A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc ^min/+ mice

Summary

Assessment of the bleeding risk of antithrombotic agents is usually performed in healthy animals with some form of vascular injury to peripheral organs to induce bleeding. However, bleeding observed in patients with currently marketed antithrombotic drugs is typically spontaneous in nature such as intracranial haemorrhage (ICH) and gastrointestinal (GI) bleeding, which happens most frequently on top of preexisting pathologies such as GI ulcerations and polyps. Apc ^min/+ mice are reported to develop multiple adenomas through the entire intestinal tract and display progressive anaemia. In this study, we evaluated the potential utility of Apc ^min/+ mice as a model for assessing spontaneous GI bleeding with antithrombotic agents. Apc ^min/+ mice exhibited progressive blood loss starting at the age of nine weeks. Despite the increase in bleeding, Apc ^min/+ mice were in a hypercoagulable state and displayed an age-dependent increase in thrombin generation and circulating fibrinogen as well as a significant decrease in clotting times. We evaluated the effect of warfarin, dabigatran etexilate, apixaban and clopidogrel in this model by administering them in diet or in the drinking water to mice for 1–4 weeks. All of these marketed drugs significantly increased GI bleeding in Apc ^min/+ mice, but not in wild-type mice. Although different exposure profiles of these antithrombotic agents make it challenging to compare the bleeding risk of compounds, our results indicate that the Apc ^min/+ mouse may be a sensitive preclinical model for assessing the spontaneous GI bleeding risk of novel antithrombotic agents.

Keywords

Antithrombotic - spontaneous - gastrointestinal - bleeding - Apc ^min/+ mice

• References

• 1 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
• 2 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
• 3 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
• 4 Holster IL, Valkhoff VE, Kuipers EJ. et al. New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis. Gastroenterology. 2013 Epub ahead of print.
• 5 Morowski M, Vogtle T, Kraft P. et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013; 121: 4938-4947.
• 6 Littlewood JD, Bevan SA, Kemball-Cook G. et al. In vivo studies of activated porcine factor VIII. Thromb Haemost 1996; 76: 743-748.
• 7 Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 06 (6 Pt 2 Suppl): 19S-23S.
• 8 Hong TT, Huang J, Driscoll E. et al. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol 2005; 46: 526-533.
• 9 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-2552.
• 10 Lind SE. Prolonged bleeding time. Am J Med 1984; 77: 305-312.
• 11 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Seminars Thromb Haemost 1990; 16: 1-20.
• 12 Horisawa S, Kaneko M, Sakurama T. SM-20302, a nonpeptide GPIIb/IIIa receptor antagonist, exhibits a wide therapeutic window in a newly developed haemorrhage model in mice. Thromb Haemost 1999; 82: 1743-1748.
• 13 Melarange R, Moore G, Blower PR. et al. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Alimentary Pharmacol Therap 1992; 06: 67-77.
• 14 Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-324.
• 15 Korinek V, Barker N, Morin PJ. et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-1787.
• 16 Morin PJ, Sparks AB, Korinek V. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
• 17 Chintala M, Strony J, Yang B. et al. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscl Thromb Vasc Biol 2010; 30: 2143-2149.
• 18 Niho N, Takahashi M, Kitamura T. et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003; 63: 6090-6095.
• 19 Sun S, Wang M, Su L. et al. Study on warfarin plasma concentration and its correlation with international normalized ratio. J Pharm Biomed Analysis 2006; 42: 218-222.
• 20 Clemens A, Haertter S, Friedman J. et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012; 28: 195-201.
• 21 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 22 Harlow P. pharmacology review(s) of Drug Approval Package, Eliquis, application No: 202155. FDA. 2012: 138.
• 23 Leil TA, Feng Y, Zhang L. et al. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Therap 2010; 88: 375-382.